GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Senseonics Holdings SENS · USD

Health Care · US listing · 🇺🇸 United States

Compare

8.02

-9.94%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Senseonics Holdings — daily SENS Delayed
Market value
$334.7m
Last close × shares
Volume
1.4m
Shares, 20 Nov 2026

About Senseonics Holdings

From its filings with the US Securities and Exchange Commission

SEC filings

Senseonics Holdings is based in Germantown, Maryland and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SENS. The SEC classifies its business as industrial instruments for measurement, display, and control. In the fiscal year to 31 December 2025, it reported revenue of $35.3m and a net loss of $69.1m. At that date it held total assets of $126.3m and shareholders' equity of $61.0m.

In its own words

We are a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (“CGM”) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Our implantable CGM system (“Eversense”), including Eversense E3 and Eversense 365 CGM systems are designed to continually and accurately measure glucose levels in people with diabetes via an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to twelve months in the case of Eversense 365 and six months in the case of Eversense E3, as compared to seven to 15 days for non-implantable CGM systems. In September 2024, the 365-day extended life Eversense E3 CGM system was approved by the FDA and, through Ascensia Diabetes Care Holdings AG (“Ascensia”), we began commercializing Eversense 365 in the fourth quarter of 2024. In January 2026, we took over full commercial responsibility for Eversense 365 in the United States and began marketing and distributing the product with our own sales force. In June 2022, we affixed the CE Mark to the Eversense E3 CGM system and Ascensia began commercialization in select markets in Europe during the third quarter of 2022. In January 2026, the Company obtained CE Mark approval for Eversense 365 and expects to launch Eversense 365 in the European Territories by the second half of 2026.

Quoted from its 10-K, filed 2 Mar 2026. Read the filing on SEC.gov ↗

More about Senseonics Holdings →

Latest on Senseonics Holdings

Our reporting

We have not reported on Senseonics Holdings yet.

Next results

1 Mar 2027

Due on 1 Mar 2027. Analysts expect earnings of -0.41 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Senseonics Holdings's ticker?

Senseonics Holdings trades as SENS on its US listing, under ISIN US81727U3032.

What was Senseonics Holdings's last closing price?

8.02 on 20 Nov 2026. The figure is in USD and is never converted.

When does Senseonics Holdings next report results?

Results are expected on 9 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.